Expression of 5-lipoxygenase in human colorectal cancer

World Journal of Gastroenterology

Volumn 12, Issue 39, 2006, Pages 6355-6360

  Soumaoro, Labile Togba ^a,b   Iida, Satoru ^a   Uetake, Hiroyuki ^a   Ishiguro, Megumi ^a   Takagi, Yoko ^a   Higuchi, Tetsuro ^a   Yasuno, Masamichi ^a   Enomoto, Masayuki ^a   Sugihara, Kenichi ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b Service de Chirurgie Generale   (Guinea)

Author keywords

5 Lipoxygenase; Arachidonic acid; Colorectal cancer; Cyclooxygenase 2; Immunohisto chemistry; Real time PCR

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; CYCLOOXYGENASE 2; MESSENGER RNA;

ADULT; AGED; ARTICLE; CANCER INHIBITION; CANCER INVASION; CANCER SIZE; CARCINOGENESIS; COLORECTAL CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE; TREATMENT PLANNING; TUMOR VASCULARIZATION; UPREGULATION;

EID: 33750813875     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v12.i39.6355     Document Type: Article

References (38)

1. Hennig R, Ding XZ, Tong WG, Schneider MB, Standop J, Friess H, Budder MW, Pour PM, Adrian TE. 5-Lipoxygenase and leukotriene B(4) receptor are expressed in human pancreatic cancers but not in pancreatic ducts in normal tissue. Am J Pathol 2002; 161: 421-428
2. Ghosh J, Myers CE. Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells. Proc Natl Acad Sci USA 1998; 95: 13182-13187
3. Romano M, Claria J. Cyclooxygenase-2 and 5-lipoxygenase converging functions on cell proliferation and tumor angiogenesis: implications for cancer therapy. FASEB J 2003; 17: 1986-1995
4. Leval X, Julemont F, Delarge J, Pirotte B, Dogne JM. New trends in dual 5-LOX/COX inhibition. Curr Med Chem 2002; 9: 941-962
5. Ikawa H, Kamitani H, Calvo BF, Foley JF, Eling TE. Expression of 15-lipoxygenase-1 in human colorectal cancer. Cancer Res 1999; 59: 360-366
6. Yamamoto S. Mammalian lipoxygenases: molecular structures and functions. Biochim Biophys Acta 1992; 1128: 117-131
7. Steele VE, Holmes CA, Hawk ET, Kopelovich L, Lubet RA, Crowell JA, Sigman CC, Kelloff GJ. Lipoxygenase inhibitors as potential cancer chemopreventives. Cancer Epidemiol Biomarkers Prev 1999; 8: 467-483
8. Wang D, Mann JR, DuBois RN. The role of prostaglandins and other eicosanoids in the gastrointestinal tract. Gastroenterology 2005; 128: 1445-1461
9. Cao Y, Prescott SM. Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J Cell Physiol 2002; 190: 279-286
10. Chulada PC, Thompson MB, Mahler JF, Doyle CM, Gaul BW, Lee C, Tiano HF, Morham SG, Snuthies O, Langenbach R. Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res 2000; 60: 4705-4708
11. Hase T, Yoshimura R, Matsuyama M, Kawahito Y, Wada S, Tsuchida K Sano H, Nakatani T. Cyclooxygenase-1 and -2 in human testicular tumours. Eur J Cancer 2003; 39: 2043-2049
12. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su LK, Levin B. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000; 342: 1946-1952
13. Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, Petrelli N, Pipas JM, Karp DD, Loprinzi CL, Steinbach G, Schilsky R. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003; 348: 883-890
14. Reardon DA, Quinn JA. Vredenburgh J, Rich JN, Gururangan S, Badruddoja M, Herndon JE 2nd, Dowell JM, Friedman AH, Friedman HS. Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. Cancer 2005; 103: 329-338
15. Milella M, Gelibter A, Di Cosimo S, Bria E, Ruggeri EM, Carlini P, Malaguti P, Pellicciotta M, Terzoli E, Cognetti F. Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma. Cancer 2004; 101: 133-138
16. Gupta S, Srivastava M, Ahmad N, Sakamoto K, Bostwick DG, Mukhtar H. Lipoxygenase-5 is overexpressed in prostate adenocarcinoma. Cancer 2001; 91: 737-743
17. Yoshimura R, Matsuyama M, Tsuchida K, Kawahito Y, Sano H, Nakatard T. Expression of lipoxygenase in human bladder carcinoma and growth inhibition by its inhibitors. J Urol 2003; 170: 1994-1999
18. Hong SH, Avis I, Vos MD, Martinez A, Treston AM, Mulshine JL. Relationship of arachidonic acid metabolizing enzyme expression in epithelial cancer cell lines to the growth effect of selective biochemical inhibitors. Cancer Res 1999; 59: 2223-2228
19. Ohd JF, Nielsen CK, Campbell J, Landberg G, Lofberg H, Sjolander A. Expression of the leukotriene D4 receptor CysLT1, COX-2 and other cell survival factors in colorectal adenocarcinomas. Gastroenterology 2003; 124: 57-70
20. Hennig R, Grippo P, Ding XZ, Rao SM, Buchler MW, Friess H, Talamonti MS, Bell RH, Adrian TE. 5-Lipoxygenase, a marker for early pancreatic intraepithelial neoplastic lesions. Cancer Res 2005; 65: 6011-6016
21. Li N, Sood S, Wang S, Fang M, Wang P, Sun Z, Yang CS, Chen X. Overexpression of 5-lipoxygenase and cyclooxygenase 2 in hamster and human oral cancer and chemopreventive effects of zileuton and celecoxib. Clin Cancer Res 2005; 11: 2089-2096
22. Chen X, Wang S, Wu N, Sood S, Wang P, Jin Z, Beer DG, Giordano TJ, Lin Y, Shih WC, Lubet RA, Yang CS. Overexpression of 5-lipoxygenase in rat and human esophageal adenocarcinoma and inhibitory effects of zileuton and celecoxib on carcinogenesis. Clin Cancer Res 2004; 10: 6703-6709
23. Avis I, Hong SH, Martinez A, Moody T, Choi YH, Trepel J, Das R, Jett M, Mulshine JL. Five-lipoxygenase inhibitors can mediate apoptosis in human breast cancer cell fines through complex eicosanoid interactions. FASEB J 2001; 15: 2007-2009
24. Romano M, Catalano A, Nutini M, D'Urbano E, Crescenzi C, Claria J, Libner R, Davi G, Procopio A. 5-lipoxygenase regulates malignant mesothelial cell survival: involvement of vascular endothelial growth factor. FASEB J 2001; 15: 2326-2336
25. Hoque A, Lippman SM, Wu TT, Xu Y, Liang ZD, Swisher S, Zhang H, Cao L, Ajani JA, Xu XC. Increased 5-lipoxygenase expression and induction of apoptosis by its inhibitors in esophageal cancer: a potential target for prevention. Carcinogenesis 2005; 26: 785-791
26. Matsuyama M, Yoshimura R, Tsuchida K, Takemoto Y, Segawa Y, Shinnka T, Kawahito Y, Sano H, Nakatani T. Lipoxygenase inhibitors prevent urological cancer cell growth. Int J Mol Med 2004; 13: 665-668
27. Shureiqi I, Wojno KJ, Poore JA, Reddy RG, Moussalli MJ, Spindler SA, Greenson JK, Normolle D, Hasan AA, Lawrence TS, Brenner DE. Decreased 13-S-hydroxyoctadecadienoic acid levels and 15-lipoxygenase-1 expression in human colon cancers. Carcinogenesis 1999; 20: 1985-1995
28. Heslin MJ, Hawkins A, Boedefeld W, Arnoletti JP, Frolov A, Soong R, Urist MM, Bland KI. Tumor-associated down-regulation of 15-lipoxygenase-1 is reversed by celecoxib in colorectal cancer. Ann Surg 2005; 241: 941-946; discussion 946-947
29. Jack GS, Brash AR, Olson SJ, Manning S, Coffey CS, Smith JA Jr, Shappell SB. Reduced 15-lipoxygenase-2 immunostaining in prostate adenocarcinoma: correlation with grade and expression in high-grade prostatic intraepithelial neoplasia. Hum Pathol 2000; 31: 1146-1154
30. Hermanek P, Sobin LH, UICC/TNM classification of malignant tumors. 4th ed, New York: Springer-verlag, 1987: 47-49
31. Chotteau-Lelievre A, Revillion F, Lhotellier V, Hornez L, Desbiens X, Cabaret V, de Launoit Y, Peyrat JP. Prognostic value of ERM gene expression in human primary breast cancers. Clin Cancer Res 2004; 10: 7297-7303
32. Soumaoro LT, Uetake H, Higuchi T, Takagi Y, Enomoto M, Sugihara K. Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer. Clin Cancer Res 2004; 10: 8465-8471
33. Ohno R, Yoshinaga K, Fujita T, Hasegawa K, Iseki H, Tsunozaki H, Ichikawa W, Nihei Z, Sugihara K. Depth of invasion parallels increased cyclooxygenase-2 levels in patients with gastric carcinoma. Cancer 2001; 91: 1876-1881
34. Ye YN, Liu ES, Shin VY, Wu WK Cho CH. Contributory role of 5-lipoxygenase and its association with angiogenesis in the promotion of inflammation-associated colonic tumorigenesis by cigarette smoking. Toxicology 2004; 203: 179-188
35. Schwartz GK, Weitzman A, O'Reilly E, Brail L, de Alwis DP, Cleverly A, Barile-Thiem B, Vinciguerra V, Budman DR. Phase I and pharmacokinetic study of LY293111, an orally bioavailable LTB4 receptor antagonist, in patients with advanced solid tumors. J Clin Oncol 2005; 23: 5365-5373
36. Krotz F, Schiele TM, Klauss V, Sohn HY. Selective COX-2 inhibitors and risk of myocardial infarction. J Vasc Res 2005; 42: 312-324
37. Ye YN, Wu WK, Shin VY, Bruce IC, Wong BC, Cho CH. Dual inhibition of 5-LOX and COX-2 suppresses colon cancer formation promoted by cigarette smoke. Carcinogenesis 2005; 26: 827-834
38. Alvaro-Gracia JM. Licofelone - clinical update on a novel LOX/COX inhibitor for the treatment of osteoarthritis. Rheumatology (Oxford) 2004; 43 Suppl 1: i21-i25